StockPriceToday

Intuitive Surgical Inc (ISRG)

ISRG stock price

Intuitive Surgical Inc. develops, manufactures, and markets robotic products designed to improve clinical outcomes for patients through minimally invasive surgery worldwide.

About Intuitive Surgical Inc

Intuitive Surgical Inc. develops, manufactures, and markets robotic surgical systems designed to enable minimally invasive surgery worldwide. The company's pioneering role in robotic surgery has made ISRG stock price sensitive to surgical procedure volumes and adoption rates of robotic surgical technology.

Intuitive Surgical's da Vinci surgical system allows surgeons to perform complex procedures through small incisions using robotic technology, resulting in potentially faster patient recovery times and improved surgical outcomes. The company's systems are used across various surgical specialties including urology, gynecology, and general surgery.

The company generates revenue through system sales, instrument and accessory sales, and service contracts, creating multiple revenue streams from its installed base. Intuitive Surgical's recurring revenue from instruments and services provides stability while new system placements drive growth, positively affecting ISRG stock price trends.

Intuitive Surgical's continued innovation in robotic surgical technology and expansion into new surgical applications position it well for long-term growth in the medical device market. The company's strong market position and the increasing adoption of minimally invasive surgical techniques remain important factors in its market valuation and future success.

ISRG Stock 12 Month Chart


Latest News for ISRG

Medical technology company Intuitive Surgical (NASDAQ:ISRG) will be announcing earnings results this Tuesday afternoon. Here’s what to expect.

You know, I have to tell you, things have gotten tough for these guys. There’s a lot of people that have moved into their industry.

Intuitive Surgical, Inc. ISRG is set to report third-quarter 2025 earnings on Oct. 21. The Zacks Consensus Estimate for sales and earnings is pegged at $2.41 billion and $1.99 per share, respectively.